Did you know that our JADPRO Cardio-Oncology Updates website is full of resources and information to help you and your patients manage cancer treatment–related cardiotoxicities? Make sure to check out our real-world case studies, specially curated news and literature articles, treatment guidelines and recommendations, Fast Fact PDFs, and expert video series. All of our offerings are organized by drug class, so you can easily find helpful information on cardiotoxicities associated with HER2-targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies.

This month, we’re excited to bring you four more real-world, drug class–specific case studies, each selected by our expert section editors to fuel your cardio-oncology practice. These resources join our growing library of updated news and literature articles, treatment guidelines and recommendations, Fast Fact PDFs, and unique expert video series installments—all focused on helping you manage cardiotoxicities associated with HER2-targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies.

Happy New Year! Start 2021 off on the right foot by checking out the drug class–specific cardio-oncology news and literature articles and resources that we’ve selected just for you. We’ve also created real-world case studies, Fast Facts handouts, and an expert video series—all focused on cardiotoxicities associated with HER2 targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies—to equip you for a successful year ahead!

Happy holidays from all of us at JADPRO Cardio-Oncology Updates! This month, we’re spotlighting recent news and literature articles and helpful drug class–specific resources in the world of HER2-targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies. And if you haven’t done so already, check out our Fast Facts handouts, case studies, and video series installments featuring in-depth discussions with our expert section editors.

We’re excited to present four more real-world case studies this month, detailing the detection, mitigation, and management of cardiotoxicities associated with one of our four profiled drug classes: HER2-targeted therapies, kinase inhibitors, immune checkpoint inhibitors, and novel immunotherapies. And as always, we've curated up-to-date news and literature articles and resources to empower you in your cardio-oncology practice.

Did you catch Dr. Kejal Amin and me presenting our CE-certified talk on cardio-oncology during JADPRO Live Virtual? We were pleased to receive so many interesting questions from viewers, which we had fun addressing through the chat panel and Q&A. If you’re registered for the meeting, you can catch our conversation on demand from November 20 through December 31. If not, there's still time to register for the meeting.

This month, we're excited to share with you the four final installments in our video series. Learn from our section editors as they discuss how to mitigate and manage cancer therapy-associated cardiotoxicities based on the specific drug class, as well as guideline recommendations and cutting-edge research. As always, we've also added updated news/literature articles and resources to equip and keep you up to date on the latest in the cardio-oncology.

Next up in our video series, we have four new episodes packed with data and best practices on the incidence, mitigation, and management of cardiotoxicities associated with HER2-targeted therapies, immune checkpoint inhibitor therapies, kinase inhibitors, and novel immunotherapies. In these new videos, our section editors and I talk about patient risk factors, toxicity management strategies, and the importance of multidisciplinary practice.

We’re also excited to bring you updated drug class–specific news/literature articles and resources, providing cutting-edge data and information in the field of cardio-oncology.

This month, the JADPRO Cardio-Oncology Updates faculty and I are excited to bring you four more real-life case studies focusing on the detection and treatment of cardiotoxicities associated with HER2-targeted therapies, immune checkpoint inhibitors, novel immunotherapies, and kinase inhibitors. In addition, you’ll find all-new news/literature and resource updates providing cutting-edge data in the field of cardio-oncology.

In the months ahead, we’ll be publishing more informative episodes from our video series, featuring our expert section editors discussing the latest data on incidence, mitigation, and management of drug class-specific cardiotoxicities with me. So stay tuned!

This month, we’re bringing you the latest and greatest updates in the field of cardio-oncology. We’ve refreshed our drug class–specific news/literature and resource sections, and we’ve added links to reviews on how COVID-19 and the associated pandemic is impacting the care and management of cardio-oncology patients, as well as strategies to continue providing high-quality care to this at-risk patient population.

Also, make sure to watch my video interviews with Kejal Amin, PharmD, MBA, BCOP, clinical pharmacist at the Smilow Cancer Center at Yale-New Haven Hospital. She and I discuss cardiotoxicities associated with HER2-targeted therapies, novel immunotherapies, kinase inhibitors, and immune checkpoint inhibitors from a pharmacological perspective, including mechanisms of toxicity, contraindications, and patient risk factors. And stay tuned for more informative and insightful video interviews with other experts throughout the coming months.

I hope you’ve been enjoying and learning from our new JADPRO Cardio-Oncology Updates offering! In addition to the current myriad drug class–specific resources—all curated by our expert faculty—the site now features a narrated Basics 101 presentation that you can view online or download and watch with your colleagues. This resource covers multiple important topics, including the link between cancer, treatment, and heart disease, current cardio-oncology standards of care, cancer treatment–related cardiotoxicity, and much more.

As we are all still experiencing, practicing in the age of COVID-19 is incredibly challenging. In cardio-oncology, this novel coronavirus has presented us with more than one reason for the cardiac side effects we commonly see with chemotherapy and/or radiation. COVID-19 has brought us heart failure, myocarditis, Takotsubo cardiomyopathy, and acute coronary syndrome (Ma L et al., 2020). We have commonly used ACE inhibitors and ARBs as cardio-protection during cancer therapy, but we now view them as possible contributors to blocking the renin-angiotensin pathway attenuating the severe lung injury seen with this viral infection. Research is still under way to answer the many questions we have about the role of ACE2 in COVID-19–induced cardiac injury and the mechanism of action that may produce this attenuation (Gosain R et al., 2020).

And as someone who uses their stethoscope as a diagnostic tool, COVID-19 has also inhibited my opportunity to lay hands on patients. I have become acutely aware of what we have taught our students over the years: the importance of a thorough history and thorough review of the medical record, which have now become the center piece of the assessment and plan of care. Even as an experienced clinician, I am becoming more of a master at digging in deep during the interview. The patient’s story is an important piece of the diagnosis puzzle, and our ability to think critically about their issue in the context of their overall clinical journey is all that some of us have right now to manage the complexities of their response to cancer treatment in the confines of the COVID-19 pandemic.

Welcome to JADPRO Cardio-Oncology Updates! This new platform is a comprehensive resource for advanced practitioners (APs) on the rapidly emerging and complex field of cardio-oncology. The prevention, early detection, and optimal treatment of cardiovascular disease in patients treated for cancer is a vital aspect of care—one in which APs play a key role. Thus, it is crucial that the AP audience is equipped with the most up-to-date research and cardio-oncology care recommendations and management strategies.

Organized by four discrete drug classes—HER2-targeted therapies, immune checkpoint inhibitors, kinase inhibitors, and novel immunotherapies—this website offers curated cutting-edge research and helpful resources on key cardiotoxicities, a Cardio-Oncology Basics 101 presentation, Fast Facts handout, case studies, and video discussions regarding cardio-oncology best practices and management strategies between expert APs. Along with four dedicated section editors and experts in the field, I'm excited to bring you the latest and greatest information and resources in cardio-oncology.

Learn more about this new offering and what’s to come in my welcome video.